GSA Capital Partners LLP Sells 2,557 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

GSA Capital Partners LLP decreased its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 165,575 shares of the company’s stock after selling 2,557 shares during the period. GSA Capital Partners LLP’s holdings in GoodRx were worth $1,149,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GDRX. American Century Companies Inc. bought a new position in shares of GoodRx during the 2nd quarter valued at approximately $18,183,000. Rubric Capital Management LP boosted its stake in GoodRx by 76.5% during the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock worth $29,147,000 after buying an additional 1,619,748 shares during the period. Millennium Management LLC raised its stake in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after acquiring an additional 1,102,758 shares during the period. Raymond James & Associates lifted its holdings in shares of GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after acquiring an additional 267,951 shares during the last quarter. Finally, Picton Mahoney Asset Management boosted its stake in shares of GoodRx by 24.3% during the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after purchasing an additional 118,703 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Down 2.1 %

NASDAQ GDRX opened at $4.56 on Friday. The firm has a market cap of $1.73 billion, a PE ratio of -155.33, a price-to-earnings-growth ratio of 3.24 and a beta of 1.39. GoodRx Holdings, Inc. has a 52 week low of $4.55 and a 52 week high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average price of $6.69 and a 200 day moving average price of $7.46.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a report on Friday, August 16th. UBS Group cut their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research note on Friday, August 9th. Finally, Citigroup reduced their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.17% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.